映恩生物-B(09606)于4月7日至4月10日招股,拟全球发售1507.16万股股份 引入BioNTech SE、LAV Star等多家基石投资者

智通财经网
07 Apr

智通财经APP讯,映恩生物-B(09606)于2025年4月7日至4月10日招股,公司拟全球发售1507.16万股股份,其中,香港发售占10%,国际发售占90%,另有超额配股权15%。每股发售价94.6-103.2港元,每手100股,预期股份将于2025年4月15日(星期二)开始在联交所买卖。我们于2019年注册成立,是全球抗体偶联药物(ADC)领域的关键领跑者,致力于为癌症和自身免疫性疾病等患者...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10